Dainippon Of Japan Licenses Cancer Drug To Boston Biomedical
This article was originally published in PharmAsia News
Executive Summary
Japan's Dainippon Sumitomo Pharma reached an agreement with Boston Biomedical to license one of U.S.-based company's cancer compounds